Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
15 hedge funds and large institutions have $454K invested in Statera Biopharma, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 2 closing their positions.
6% less funds holding
Funds holding: 16 → 15 (-1)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
56% less capital invested
Capital invested by funds: $1.03M → $454K (-$578K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$9.32K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$6.78K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$6.25K |
| 4 |
Bessemer Group
Woodbridge,
New Jersey
|
+$734 |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$423 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$110K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20.8K |
| 3 |
BlackRock
New York
|
-$442 |
| 4 |
Wells Fargo
San Francisco,
California
|
-$262 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$178 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $290K | +$9.32K | +5,400 | +2% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $108K | -$110K | -63,673 | -37% |
|
3
Geode Capital Management
Boston,
Massachusetts
| $16K | – | – | – |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $15K | -$20.8K | -12,042 | -44% |
|
|
5
BlackRock
New York
| $15K | -$442 | -256 | -2% |
|
|
6
UBS Group
Zurich,
Switzerland
| $6K | +$6.78K | +3,925 | +191% |
|
|
7
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | +$6.25K | +3,620 | +32,909% |
|
|
8
Wells Fargo
San Francisco,
California
| – | -$262 | -152 | -76% |
|
|
9
Bank of America
Charlotte,
North Carolina
| – | -$178 | -103 | -41% |
|
|
LTFS
10
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | +$423 | +245 | +1,225% |
|
|
11
Bessemer Group
Woodbridge,
New Jersey
| – | +$734 | +425 | New |
|
STAB Hedge Fund Activity: Q4 2018 in Review
15 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q4 2018, worth a combined $454K — down 56% from $1.03M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of STAB and 1 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $9.32K. The largest seller was Vanguard Group, cutting an estimated $110K.
- 15 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q4 2018, down from 16 in Q3 2018.
- Funds reported $454K of Statera Biopharma, Inc. Common Stock stock for Q4 2018, down 56% quarter-over-quarter.
- 1 fund opened new Statera Biopharma, Inc. Common Stock positions in Q4 2018 and 2 closed out, a net change of -1 holder.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q4 2018 was Renaissance Technologies, an estimated $9.32K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q4 2018 was Vanguard Group, an estimated $110K sold.
Based on aggregated 13F filings for Q4 2018.